Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03041636 · ClinicalTrials.gov registry record · Phase 2
Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT03041636: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT03041636 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03041636, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This phase II trial studies how well ruxolitinib phosphate works in treating patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma. Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG Ruxolitinib
- DRUG Ruxolitinib Phosphate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2017-03-08 |
| Est. Completion | 2020-04-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03041636
The ClinicalTrials.gov registry entry for NCT03041636 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ruxolitinib is the first listed.
NCT03041636 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03041636 about?
NCT03041636 is a clinical study titled "Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma". This phase II trial studies how well ruxolitinib phosphate works in treating patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma. Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT03041636?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2017-03-08. Estimated completion is 2020-04-29.
What interventions are being tested in trial NCT03041636?
The interventions under investigation include: Ruxolitinib (DRUG), Ruxolitinib Phosphate (DRUG).
Who is sponsoring clinical trial NCT03041636?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.